{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:59:51Z","timestamp":1790258391429,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":95,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence on the effectiveness of mepolizumab at reducing healthcare resource utilization (HCRU) and clinical symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This real-world study used linked electronic medical record and claims data from the OM1 Real-World Data Cloud of clinician networks in the US, including an ear, nose and throat physician registry. CRSwNP-related HCRU, procedures, concomitant medications, and sign and symptom outcomes were assessed in adult patients with CRSwNP who initiated mepolizumab on\/after July 29, 2021 (index date), with \u22651 mepolizumab record, data available for \u226512 months pre- and \u22656 months post-index (follow-up\/post-mepolizumab period).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was a significant difference in CRSwNP-related HCRU 6-months post- versus pre-mepolizumab initiation (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009245), mean difference in outpatient visits (95% confidence interval): \u22120.82(\u22121.10, \u22120.53),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001; otolaryngologist visits: \u22120.35(\u22120.54, \u22120.16),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0004; allergist visits: \u22120.28(\u22120.43, \u22120.14),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0001. Similar reductions were observed for all-cause HCRU. At 6-months post-mepolizumab, proportion of patients with oral corticosteroid and oral antibiotic prescriptions substantially reduced (36% pre- vs. 27% post-; and 38% pre- vs. 23% post-, respectively). There were clinically meaningful improvements in symptoms recorded 6-months post- versus pre-mepolizumab, with fewer patients experiencing anosmia (\u221253%), facial pain\/pressure (\u221235%), nasal discharge (\u221232%) and nasal obstruction (\u221229%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world practice, mepolizumab is associated with reduced HCRU and improved clinical symptoms, potentially alleviating medication burden in patients with CRSwNP. These results indicate, beyond improvements shown in randomized controlled trials, mepolizumab may reduce HCRU disease burden as early as 6-months post-initiation. This study offers real-world insight that may support clinical decision-making with mepolizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-026-01038-w","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T22:24:06Z","timestamp":1781994246000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mepolizumab reduces healthcare resource utilization in patients with chronic rhinosinusitis with nasal polyps: a linked EMR and claims-based pre-post study"],"prefix":"10.1186","volume":"22","author":[{"given":"Anna","family":"Swenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Edgecomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gliklich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"issue":"1","key":"1038_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","volume":"197","author":"TF Carr","year":"2018","unstructured":"Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1038_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2466-14-112","volume":"14","author":"O Eltboli","year":"2014","unstructured":"Eltboli O, Bafadhel M, Hollins F, Wright A, Hargadon B, Kulkarni N, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14(1):112.","journal-title":"BMC Pulm Med"},{"issue":"5","key":"1038_CR3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","volume":"137","author":"P Tomassen","year":"2016","unstructured":"Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449\u2013e564.","journal-title":"J Allergy Clin Immunol"},{"key":"1038_CR4","unstructured":"FDA. Mepolizumab (Nucala) Prescribing Information. 2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761122s022lbl.pdf. Accessed 26 March 2026."},{"issue":"10","key":"1038_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1038_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2024.06.033","volume":"133","author":"JA Bernstein","year":"2024","unstructured":"Bernstein JA, Silver J, Packnett E, Lew CR, Robles Y, Deb A. Real-world unified airway benefits of mepolizumab: effectiveness in patients with asthma and comorbid nasal polyps. Ann Allergy Asthma Immunol. 2024;133(4):422\u2013e92.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1038_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/alr.23220","volume":"14","author":"J Silver","year":"2024","unstructured":"Silver J, Deb A, Lalibert\u00e9 F, Gao C, Bhattacharyya N. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. Int Forum Allergy Rhinol. 2024;14(1):5\u201317.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"11","key":"1038_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3390\/jpm14111112","volume":"14","author":"E Cantone","year":"2024","unstructured":"Cantone E, Cassiano B, Pezzella P, Russo MB, Detoraki A. The effects of mepolizumab on CRSwNP: real-life evidence. J Pers Med. 2024;14(11):1112.","journal-title":"J Pers Med"},{"issue":"12","key":"1038_CR9","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.3390\/jcm13123575","volume":"13","author":"C Cavaliere","year":"2024","unstructured":"Cavaliere C, Loperfido A, Ciofalo A, Di Michele L, Begvarfaj E, Bellocchi G, et al. Real-life evidence of mepolizumab treatment in chronic rhinosinusitis with nasal polyps: a multicentric study. J Clin Med. 2024;13(12):3575.","journal-title":"J Clin Med"},{"issue":"2","key":"1038_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biomedicines11020485","volume":"11","author":"MS Dom\u00ednguez-Sosa","year":"2023","unstructured":"Dom\u00ednguez-Sosa MS, Cabrera-Ram\u00edrez MS, Marrero-Ramos MDC, D\u00e1vila-Quintana D, Cabrera-L\u00f3pez C, Carrillo-D\u00edaz T, et al. Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps. Biomedicines. 2023;11(2):485.","journal-title":"Biomedicines"},{"issue":"4","key":"1038_CR11","doi-asserted-by":"publisher","first-page":"104329","DOI":"10.1016\/j.amjoto.2024.104329","volume":"45","author":"C Galletti","year":"2024","unstructured":"Galletti C, Ciodaro F, Barbieri MA, Gambino F, Ferrisi MG, Portelli D, et al. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: real life data in a tertiary care. Am J Otolaryngol. 2024;45(4):104329.","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"1038_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00405-024-09027-8","volume":"282","author":"P Orlando","year":"2025","unstructured":"Orlando P, Vivarelli E, Minzoni A, Licci G, Accinno M, Brugnoli B, et al. Effects of mepolizumab in the treatment of type 2 CRSwNP: a real-life clinical study. Eur Arch Otorhinolaryngol. 2025;282(1):265\u201372.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"11","key":"1038_CR13","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1080\/03007995.2020.1815682","volume":"36","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Thomas K, Guiang H. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897\u2013911.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"1038_CR14","doi-asserted-by":"publisher","first-page":"AB263","DOI":"10.1016\/j.jaci.2023.11.842","volume":"153","author":"M Maldonado-Puebla","year":"2024","unstructured":"Maldonado-Puebla M, Cardet JC, Silver J, Lalibert\u00e9 F, Hilts A, Ramasubramanian R, et al. Real-world effectiveness of mepolizumab in patients with chronic rhinosinusitis with nasal polyps: a pre\/post assessment of oral corticosteroid use and sinus surgery in the US. J Allergy Clin Immunol. 2024;153(2):AB263.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1038_CR15","doi-asserted-by":"publisher","first-page":"2473974x2211289","DOI":"10.1177\/2473974X221128930","volume":"6","author":"VS Benson","year":"2022","unstructured":"Benson VS, Germain G, Chan RH, Sousa AR, Yang S, Silver J, et al. Elucidating the real-world burden of chronic rhinosinusitis with nasal polyps in patients in the USA. OTO Open. 2022;6(4):2473974x221128930.","journal-title":"OTO Open"},{"issue":"6","key":"1038_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.anai.2024.10.015","volume":"134","author":"JK Han","year":"2025","unstructured":"Han JK, Silver J, Dhangar I, Veeranki P, Deb A. Quantifying corticosteroid burden in chronic rhinosinusitis with nasal polyps: a retrospective US database study. Ann Allergy Asthma Immunol. 2025;134(6):685\u2013e935.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"1038_CR17","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","volume":"10","author":"C Pilette","year":"2022","unstructured":"Pilette C, Canonica GW, Chaudhuri R, Chupp G, Lee FE-H, Lee JK, et al. REALITI-a study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"13","key":"1038_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"4","key":"1038_CR19","doi-asserted-by":"publisher","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","volume":"56","author":"T Harrison","year":"2020","unstructured":"Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, et al. Real-world mepolizumab in the prospective severe asthma REALITI-a study: initial analysis. Eur Respir J. 2020;56(4):2000151.","journal-title":"Eur Respir J"},{"issue":"3","key":"1038_CR20","first-page":"194","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et al. EPOS\/EUFOREA update on indication and evaluation of Biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61(3):194\u2013202.","journal-title":"Rhinology"},{"issue":"2","key":"1038_CR21","first-page":"108","volume":"61","author":"C Hopkins","year":"2023","unstructured":"Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, et al. Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology. 2023;61(2):108\u201317.","journal-title":"Rhinology"},{"issue":"2","key":"1038_CR22","doi-asserted-by":"publisher","first-page":"AB126","DOI":"10.1016\/j.jaci.2020.12.462","volume":"147","author":"M Tabberer","year":"2021","unstructured":"Tabberer M, Trigg A, Busse W, Lund V, Lee J, Bachert C, et al. Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: data from the SYNAPSE study. J Allergy Clin Immunol. 2021;147(2):AB126.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-026-01038-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:40Z","timestamp":1790255260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-026-01038-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1038"],"URL":"https:\/\/doi.org\/10.1186\/s13223-026-01038-w","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was a retrospective analysis of de-identified data, therefore informed consent or ethics approval were not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AS \u2013 employed by OM1, Inc. WA \u2013 formerly employed by GSK and holds financial equities in GSK. JS \u2212 formerly employed by GSK and holds financial equities in GSK and is now employed by Amgen and holds financial equities in Amgen. SZ, AE, LZ \u2013 employed by GSK and hold financial equities in GSK. RA-C \u2013 formerly employed by GSK and holds financial equities in GSK. RG \u2013 employed by OM1, Inc. and Massachusetts Eye and Ear.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"50"}}